Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.42 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577485 | 0.90 | TSHR (0.38) | PTGDR2PTGDRPTGIRPDE10APDE4A | |
| SCHEMBL14176165 | 0.86 | PTGDR2 (0.44) | PTGDR2PTGDRPTGIRPDE10AHDAC1 | |
| SCHEMBL3327259 | 0.80 | PTGDR2 (0.42) | PTGDR2PTGDRPTGIRPDE10AHDAC1 | |
| SCHEMBL3964681 | 0.75 | PTGDR2 (0.46) | PTGDR2PTGDR | |
| SCHEMBL3968952 | 0.73 | PTGDR2 (0.43) | PTGDR2PTGDR | |
| SCHEMBL3967113 | 0.73 | PTGDR2 (0.45) | PTGDR2PTGDR | |
| SCHEMBL3968079 | 0.72 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL3327331 | 0.72 | PTGIR (0.36) | PTGDR2PTGDRPTGIRPDE10AHDAC1 | |
| SCHEMBL3968057 | 0.72 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL4636883 | 0.72 | PTGDR2 (0.44) | PTGDR2PTGDRPTGIRPDE10AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | claimed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGDR2 167/4885PTGDR 335/4885PTGIR 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.